Takashi Morisaki

Dr. Takashi Morisaki


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KOKoki Oyama
Koki Oyama
KNKohei Nakata
Kohei Nakata
TAToshiya Abe
Toshiya Abe
KHKento Hirotaka
Kento Hirotaka
NFNao Fujimori
Nao Fujimori
TMTakashi Morisaki
Takashi Morisaki
Introduction: Pancreatic cancer shows very poor prognosis and high resistance to conventional standard chemotherapy and immunotherapy; therefore, the development of new breakthrough therapies is highly desirable.Method: We retrospectively evaluated the safety and efficacy of neoantigen peptide-pulsed dendritic cell (Neo-P DC) vaccine therapy after surgical treatment of pancreatic cancer.Result: The result showed induction of neoantigen-specific T cells in 13 (81.3%) of the 16 patients who received Neo-P DC vaccines. In survival analysis of the nine patients who received Neo-P DC vaccines after recurrence, longer overall survival was observed in patients with neoantigen-specific T cell induction than those without T cell induction. Notably, only one of the seven patients who received Neo-P DC vaccines as adjuvant setting developed recurrence, and no patient died during median follow-up 61 months after surgery (range, 25-70 months). Furthermore, TCR repertoire analyses were performed in a case treated with Neo-P DC vaccine combined with long and short peptides, and one significantly dominant clone induced by the long peptide was detected among CD4+ T cell populations.Discussion: The present study suggests the feasibility and efficacy of Neo-P DC vaccine therapy after surgical treatment of pancreatic cancer in both postoperative recurrence cases and adjuvant setting. A case analysis suggests the importance of combination with long peptides targeting CD4+ T cell.

17 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
TMTakafumi Morisaki Morisaki
Takafumi Morisaki Morisaki
MKMakoto Kubo
Makoto Kubo
SMShinji Morisaki
Shinji Morisaki
MUMasayo Umebayashi
Masayo Umebayashi
HTHiroto Tanaka
Hiroto Tanaka
TMTakashi Morisaki
Takashi Morisaki
Background/Objectives: Neoantigens have attracted attention as ideal therapeutic targets for anti-tumour immunotherapy because the T cells that respond to neoantigens are not affected by central immune tolerance. Recent findings have revealed that the activation of CD4-positive T cells plays a central role in antitumor immunity, and thus targeting human leukocyte antigen (HLA) class II-restricted neoantigens, which are targets of CD4-positive T cells, is of significance. However, there are very few detailed reports of neoantigen vaccine therapies that use an HLA class II-restricted long peptide. In the present study, we retrospectively analysed the ability of HLA class II-restricted neoantigen-pulsed dendritic cell vaccines to induce immune response in five breast cancer patients. Methods: We performed whole exome and RNA sequencing of breast cancer tissues and neoantigen prediction using an in silico pipeline. We then administered dendritic cells pulsed with synthesized an HLA class II-restricted long peptide containing an epitope with high affinity to HLA class I in the lymph node. Results: ELISPOT analysis confirmed that a T-cell response specific for the HLA class II-restricted neoantigen was induced in all cases. TCR repertoire analysis of peripheral blood mononuclear cells before and after treatment in three patients showed increases of specific T-cell clones in two of the three patients. Importantly, no recurrence was observed in all patients. Conclusions: Our analysis demonstrated the immunological efficacy of the HLA class II-restricted neoantigen peptide dendritic cell vaccine against breast cancer and provides useful information for the development of neoantigen vaccine therapy for breast cancer.

16 August 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
NINaoya Iwamoto
Naoya Iwamoto
HOHideya Onishi
Hideya Onishi
SMShogo Masuda
Shogo Masuda
AIAkira Imaizumi
Akira Imaizumi
KSKeita Sakanashi
Keita Sakanashi
MNMasafumi Nakamura
Masafumi Nakamura

31 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TMTakafumi Morisaki Morisaki
Takafumi Morisaki Morisaki
TMTakashi Morisaki
Takashi Morisaki
The discovery of neoantigens and their application in cancer vaccines have brought about a paradigm shift in cancer immunotherapy, similar to the way in which immune checkpoint inhibitors redefined therapeutic strategies for cancer treatment. Early neoantigen vaccine approaches primarily focused on eliciting HLA class I-restricted CD8+ cytotoxic T lymphocyte (CTL) responses, whereas it has become clear that such strategies alone may be insufficient to establish durable and effective antitumor immunity. Increasing attention has therefore shifted toward HLA class II-restricted neoantigens (“helper neoantigens”) that activate tumor-specific CD4+ helper T cells. Recent studies have revealed that neoantigen-reactive CD4+ helper T cells play a central role in coordinating antitumor immune responses through dendritic cell licensing, thereby sustaining CD8+ CTL function, preventing T-cell exhaustion, and promoting the generation of long-lived memory T cells. These findings have highlighted the pivotal role of helper neoantigens in shaping vaccine efficacy. In this review, we discuss the mechanistic basis underlying the contribution of helper neoantigens to tumor immunity and highlight recent advances in the real-world application of helper neoantigen-based vaccine strategies.